Catherine Sautes-fridman

List of Publications by Year
in descending order

181 papers	29,900 citations	7551 77 h-index	5663 162 g-index
192 all docs	192 docs citations	192 times ranked	33660 citing authors

#	Article	IF	Citations
1	The immune contexture in human tumours: impact on clinical outcome. Nature Reviews Cancer, 2012, 12, 298-306.	12.8	3,873
2	Estimating theÂpopulation abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biology, 2016, 17, 218.	3.8	1,980
3	The immune contexture in cancer prognosis and treatment. Nature Reviews Clinical Oncology, 2017, 14, 717-734.	12.5	1,590
4	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	13.7	1,421
5	B cells are associated with survival and immunotherapy response in sarcoma. Nature, 2020, 577, 556-560.	13.7	1,158
6	Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene, 2010, 29, 1093-1102.	2.6	942
7	Tertiary lymphoid structures in the era of cancer immunotherapy. Nature Reviews Cancer, 2019, 19, 307-325.	12.8	879
8	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). European Journal of Immunology, 2019, 49, 1457-1973.	1.6	766
9	Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 832-844.	2.5	564
10	Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells. Cancer Research, 2014, 74, 705-715.	0.4	466
11	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research, 2016, 22, 4057-4066.	3.2	433
12	Tertiary lymphoid structures in cancer and beyond. Trends in Immunology, 2014, 35, 571-580.	2.9	418
13	Profound Coordinated Alterations of Intratumoral NK Cell Phenotype and Function in Lung Carcinoma. Cancer Research, 2011, 71, 5412-5422.	0.4	404
14	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
15	The clinical role of the TME in solid cancer. British Journal of Cancer, 2019, 120, 45-53.	2.9	380
16	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clinical Cancer Research, 2015, 21, 3031-3040.	3.2	355
17	Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates. Cancer Research, 2011, 71, 5601-5605.	0.4	341
18	The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies. Frontiers in Immunology, 2020, 11, 784.	2.2	339

#	Article	IF	Citations
19	A uniform activated B-cellâ€“like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood, 2006, 107, 190-196.	0.6	335
20	The Structure of a Human Type III FcÎ³ Receptor in Complex with Fc. Journal of Biological Chemistry, 2001, 276, 16469-16477.	1.6	325
21	Interleukin-17 inhibits tumor cell growth by means of a T-cellâ€“dependent mechanism. Blood, 2002, 99, 2114-2121.	0.6	309
22	Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin. Clinical Cancer Research, 2013, 19, 4079-4091.	3.2	301
23	Tertiary lymphoid structures, drivers of the antiâ€tumor responses in human cancers. Immunological Reviews, 2016, 271, 260-275.	2.8	277
24	Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 4416-4428.	3.2	252
25	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. Clinical Cancer Research, 2015, 21, 1329-1339.	3.2	250
26	Characterization of Chemokines and Adhesion Molecules Associated with T cell Presence in Tertiary Lymphoid Structures in Human Lung Cancer. Cancer Research, 2011, 71, 6391-6399.	0.4	245
27	Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. Frontiers in Immunology, 2016, 7, 407.	2.2	238
28	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. OncoImmunology, 2015, 4, e1008866.	2.1	237
29	Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Research, 1999, 59, 3698-704.	0.4	235
30	Trial watch: IDO inhibitors in cancer therapy. OncoImmunology, 2014, 3, e957994.	2.1	223
31	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 58-65.	1.8	219
32	Context-dependent roles of complement in cancer. Nature Reviews Cancer, 2019, 19, 698-715.	12.8	217
33	Differential Modulation of Stimulatory and Inhibitory FcÎ³ Receptors on Human Monocytes by Th1 and Th2 Cytokines. Journal of Immunology, 2001, 166, 531-537.	0.4	215
34	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity, 2022, 55, 527-541.e5.	6.6	215
35	CD14 ^{dim} CD16 ⁺ and CD14 ⁺ CD16 ⁺ Monocytes in Obesity and During Weight Loss. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2322-2330.	1.1	210
36	The Nonâ€“Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 377-390.	2.5	204

#	Article	IF	Citations
37	Trial watch. OncoImmunology, 2012, 1, 1323-1343.	2.1	203
38	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. OncoImmunology, 2012, 1, 894-907.	2.1	194
39	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. Current Topics in Microbiology and Immunology, 2010, 344, 1-24.	0.7	193
40	Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. Journal of Clinical Investigation, 2010, 120, 1285-1297.	3.9	191
41	Trial Watch. OncoImmunology, 2012, 1, 699-739.	2.1	184
42	B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nature Reviews Clinical Oncology, 2022, 19, 441-457.	12.5	176
43	Trial watch. OncoImmunology, 2013, 2, e24612.	2.1	175
44	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer, 2021, 2, 794-802.	5.7	173
45	Calreticulin Expression in Human Nonâ€“Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. Cancer Research, 2016, 76, 1746-1756.	0.4	164
46	Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney International, 2010, 77, 339-349.	2.6	163
47	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 2016, 130, 95-190.	1.1	160
48	Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth. Cancer Immunology Research, 2019, 7, 1091-1105.	1.6	153
49	Trial watch. OncoImmunology, 2012, 1, 1111-1134.	2.1	152
50	The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. Journal of Medical Genetics, 2009, 46, 447-450.	1.5	142
51	Hyperfunctional C3 convertase leads to complement deposition on endothelial cells and contributes to atypical hemolytic uremic syndrome. Blood, 2009, 114, 2837-2845.	0.6	140
52	Alternative complement pathway assessment in patients with atypical HUS. Journal of Immunological Methods, 2011, 365, 8-26.	0.6	140
53	The immune contexture of primary and metastatic human tumours. Current Opinion in Immunology, 2014, 27, 8-15.	2.4	137
54	Trial Watch. OncoImmunology, 2014, 3, e27878.	2.1	134

#	Article	IF	Citations
55	Trial Watch. OncoImmunology, 2013, 2, e25238.	2.1	132
56	Cancer immune contexture and immunotherapy. Current Opinion in Immunology, 2016, 39, 7-13.	2.4	132
57	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
58	Jejunal T Cell Inflammation in Human Obesity Correlates with Decreased Enterocyte Insulin Signaling. Cell Metabolism, 2015, 22, 113-124.	7.2	130
59	A prevalent C3 mutation in aHUS patients causes a direct C3 convertase gain of function. Blood, 2012, 119, 4182-4191.	0.6	128
60	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	2.9	122
61	The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. Cancer Microenvironment, 2013, 6, 117-122.	3.1	119
62	Trial watch. OncoImmunology, 2012, 1, 1557-1576.	2.1	110
63	Trial watch. OncoImmunology, 2012, 1, 179-188.	2.1	104
64	Trial Watch: Monoclonal antibodies in cancer therapy. OncoImmunology, 2012, 1, 28-37.	2.1	103
65	Characteristics of tertiary lymphoid structures in primary cancers. OncoImmunology, 2013, 2, e26836.	2.1	103
66	Trial Watch. OncoImmunology, 2013, 2, e26621.	2.1	101
67	Crystal Structure of the Extracellular Domain of a Human FcÎ³RIII. Immunity, 2000, 13, 387-395.	6.6	98
68	Trial Watch: Peptide-based anticancer vaccines. OncoImmunology, 2015, 4, e974411.	2.1	97
69	Overall Neutralization of Complement Factor H by Autoantibodies in the Acute Phase of the Autoimmune Form of Atypical Hemolytic Uremic Syndrome. Journal of Immunology, 2012, 189, 3528-3537.	0.4	96
70	Tumor microenvironment is multifaceted. Cancer and Metastasis Reviews, 2011, 30, 13-25.	2.7	95
71	Trial watch. OncoImmunology, 2013, 2, e22789.	2.1	92
72	Profiling of the Three Circulating Monocyte Subpopulations in Human Obesity. Journal of Immunology, 2015, 194, 3917-3923.	0.4	92

#	Article	IF	Citations
73	B cells and cancer: To B or not to B?. Journal of Experimental Medicine, 2021, 218, .	4.2	91
74	Transcriptomic analysis of the tumor microenvironment to guide prognosis and immunotherapies. Cancer Immunology, Immunotherapy, 2018, 67, 981-988.	2.0	89
75	Trial Watchâ€"Oncolytic viruses and cancer therapy. OncoImmunology, 2016, 5, e1117740.	2.1	88
76	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nature Medicine, 2022, 28, 1199-1206.	15.2	88
77	Trial Watch. OncoImmunology, 2013, 2, e25595.	2.1	83
78	TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Nonâ€"Small Cell Lung Cancer. Cancer Research, 2014, 74, 5008-5018.	0.4	83
79	Fc Î³ receptors. Immunology Letters, 2004, 92, 199-205.	1.1	82
80	PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. European Urology Focus, 2019, 5, 192-196.	1.6	81
81	Dendritic cells in the tumor microenvironment: prognostic and theranostic impact. Seminars in Immunology, 2020, 48, 101410.	2.7	81
82	The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status. Chest, 2014, 146, 633-643.	0.4	80
83	Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. Blood, 2002, 100, 3646-3655.	0.6	78
84	Structural basis of the interaction between IgG and fcÎ³ receptors. Journal of Molecular Biology, 2000, 295, 213-224.	2.0	76
85	Trial Watch. OncoImmunology, 2014, 3, e29179.	2.1	76
86	TRAF4 overexpression is a common characteristic of human carcinomas. Oncogene, 2007, 26, 142-147.	2.6	72
87	Trial Watch. OncoImmunology, 2012, 1, 306-315.	2.1	70
88	Trial Watch. OncoImmunology, 2014, 3, e27048.	2.1	69
89	Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. Journal of Autoimmunity, 2011, 36, 9-15.	3.0	67
90	Nivolumab, nivolumabâ€"ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 612-624.	5.1	66

#	Article	IF	Citations
91	Measles virus nucleoprotein induces cell-proliferation arrest and apoptosis through NTAILâ€“NR and NCOREâ€“FcÎ³RIIB1 interactions, respectively. Journal of General Virology, 2005, 86, 1771-1784.	1.3	65
92	The Immune Microenvironment: A Major Player in Human Cancers. International Archives of Allergy and Immunology, 2014, 164, 13-26.	0.9	63
93	The murine Microenvironment Cell Population counter method to estimate abundance of tissue-infiltrating immune and stromal cell populations in murine samples using gene expression. Genome Medicine, 2020, 12, 86.	3.6	63
94	Association of FcÎ³RII with Low-Density Detergent-Resistant Membranes Is Important for Cross-Linking-Dependent Initiation of the Tyrosine Phosphorylation Pathway and Superoxide Generation. Journal of Immunology, 2001, 167, 5814-5823.	0.4	61
95	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. Clinical Cancer Research, 2019, 25, 7351-7362.	3.2	61
96	Murine Models of B-Cell Lymphomas: Promising Tools for Designing Cancer Therapies. Advances in Hematology, 2012, 2012, 1-13.	0.6	60
97	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. , 2020, 8, e000979.		60
98	Association of IL-36Î³ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. Cancer Immunology, Immunotherapy, 2019, 68, 109-120.	2.0	59
99	Complement System: Promoter or Suppressor of Cancer Progression?. Antibodies, 2020, 9, 57.	1.2	58
100	Lung Tumor Microenvironment Induces Specific Gene Expression Signature in Intratumoral NK Cells. Frontiers in Immunology, 2013, 4, 19.	2.2	56
101	Cytokine Profile in Human Eyes: Contribution of a New Cytokine Combination for Differential Diagnosis between Intraocular Lymphoma or Uveitis. PLoS ONE, 2013, 8, e52385.	1.1	55
102	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). OncoImmunology, 2015, 4, e1049804.	2.1	51
103	The immune response in cancer: from immunology to pathology to immunotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 127-135.	1.4	51
104	Therapeutic Targeting of the Colorectal Tumor Stroma. Gastroenterology, 2020, 158, 303-321.	0.6	51
105	C1q+ macrophages: passengers or drivers of cancer progression. Trends in Cancer, 2022, 8, 517-526.	3.8	51
106	Quantitative Analyses of the Tumor Microenvironment Composition and Orientation in the Era of Precision Medicine. Frontiers in Oncology, 2018, 8, 390.	1.3	46
107	Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer. Seminars in Immunology, 2020, 48, 101406.	2.7	44
108	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. Clinical Cancer Research, 2020, 26, 4381-4389.	3.2	44

#	Article	IF	Citations
109	Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunology Research, 2021, 9, 891-908.	1.6	43
110	Regulation of production of soluble Fcî³ receptors type III in normal and pathological conditions. Immunology Letters, 1999, 68, 125-134.	1.1	41
111	Intracellular Factor H Drives Tumor Progression Independently of the Complement Cascade. Cancer Immunology Research, 2021, 9, 909-925.	1.6	40
112	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clinical Cancer Research, 2021, 27, 6749-6760.	3.2	39
113	Tumor microenvironment in NSCLC suppresses NK cells function. OncoImmunology, 2012, 1, 244-246.	2.1	34
114	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 2019, 17, e981-e994.	0.9	34
115	FADD protein release mirrors the development and aggressiveness of human non-small cell lung cancer. British Journal of Cancer, 2012, 106, 1989-1996.	2.9	33
116	Preclinical Study of Ublituximab, a Glycoengineered Anti-Human CD20 Antibody, in Murine Models of Primary Cerebral and Intraocular B-Cell Lymphomas. , 2013, 54, 3657.		33
117	Soluble CD16 Inhibits CR3 (CD11b/CD18)-Mediated Infection of Monocytes/Macrophages by Opsonized Primary R5 HIV-1. Journal of Immunology, 2001, 166, 3377-3383.	0.4	32
118	Mannose Receptor Ligand-Positive Cells Express the Metalloprotease Decysin in the B Cell Follicle. Journal of Immunology, 2001, 167, 5052-5060.	0.4	31
119	Impaired Th1/Tc1 Cytokine Production of Tumor-Infiltrating Lymphocytes in a Model of Primary Intraocular B-Cell Lymphoma. , 2007, 48, 3223.		31
120	Selective expression of inhibitory Fcî³ receptor by metastatic melanoma impairs tumor susceptibility to IgGâ€dependent cellular response. International Journal of Cancer, 2008, 123, 2832-2839.	2.3	31
121	Hereditary complement C7 deficiency in nine families: Subtotal C7 deficiency revisited. European Journal of Immunology, 2007, 37, 1377-1385.	1.6	30
122	Shaping of an effective immune microenvironment to and by cancer cells. Cancer Immunology, Immunotherapy, 2014, 63, 991-997.	2.0	30
123	Revisiting immune escape in colorectal cancer in the era of immunotherapy. British Journal of Cancer, 2019, 120, 815-818.	2.9	30
124	Immune-based identification of cancer patients at high risk of progression. Current Opinion in Immunology, 2018, 51, 97-102.	2.4	29
125	Modulation of tumor growth by inhibitory Fcî³ receptor expressed by human melanoma cells. Journal of Clinical Investigation, 2002, 110, 1549-1557.	3.9	29
126	Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis. Journal of Autoimmunity, 2008, 30, 238-245.	3.0	28

#	Article	IF	Citations
127	Control of tumor development by intratumoral cytokines. Immunology Letters, 1999, 68, 135-139.	1.1	27
128	Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. OncoImmunology, 2014, 3, e28976.	2.1	26
129	Trial watch: Naked and vectored DNA-based anticancer vaccines. OncoImmunology, 2015, 4, e1026531.	2.1	26
130	LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naÃ¯ve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. Annals of Oncology, 2020, 31, S1157.	0.6	26
131	Review of Prognostic Expression Markers for Clear Cell Renal Cell Carcinoma. Frontiers in Oncology, 2021, 11, 643065.	1.3	26
132	FcÎ³RIIB is differentially expressed during B cell maturation and in B-cell lymphomas. British Journal of Haematology, 2004, 124, 55-62.	1.2	25
133	Characterization of immune functions in TRAF4â€deficient mice. Immunology, 2008, 124, 562-574.	2.0	25
134	TLS in Tumors: What Lies Within. Trends in Immunology, 2016, 37, 1-2.	2.9	24
135	N-glycosylation profile of recombinant human soluble FcÂ receptor III. Glycobiology, 2002, 12, 507-515.	1.3	22
136	Th17 Cells Are Involved in the Local Control of Tumor Progression in Primary Intraocular Lymphoma. PLoS ONE, 2011, 6, e24622.	1.1	21
137	Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models. Journal of Visualized Experiments, 2016, , .	0.2	21
138	Site-specific N-glycosylation analysis of soluble FcÎ³ receptor IIIb in human serum. Scientific Reports, 2018, 8, 2719.	1.6	21
139	Immune adaptive microenvironment profiles in intracerebral and intrasplenic lymphomas share common characteristics. Clinical and Experimental Immunology, 2011, 165, 329-337.	1.1	17
140	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 463-474.	1.4	16
141	Fc gamma receptors and cancer. Seminars in Immunopathology, 2006, 28, 321-328.	4.0	15
142	Metastatic Melanomas Express Inhibitory Low Affinity Fc Gamma Receptor and Escape Humoral Immunity. Dermatology Research and Practice, 2010, 2010, 1-11.	0.3	15
143	PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.. Journal of Clinical Oncology, 2021, 39, 11507-11507.	0.8	15
144	Influence of Tumor Location on the Composition of Immune Infiltrate and Its Impact on Patient Survival. Lessons from DCBCL and Animal Models. Frontiers in Immunology, 2012, 3, 98.	2.2	14

#	Article	IF	Citations
145	Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. Oncologist, 2022, 27, 501-511.	1.9	14
146	Activation of Human Peripheral IgM+ B Cells Is Transiently Inhibited by BCR-Independent Aggregation of FcÎ³RIIB. Journal of Immunology, 2008, 181, 5350-5359.	0.4	13
147	Lymphoma B-cell responsiveness to CpG-DNA depends on the tumor microenvironment. Journal of Experimental and Clinical Cancer Research, 2013, 32, 18.	3.5	13
148	Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study. , 2022, 10, e004885.		13
149	Modulation of tumor growth by inhibitory FcÎ³ receptor expressed by human melanoma cells. Journal of Clinical Investigation, 2002, 110, 1549-1557.	3.9	12
150	Presentation of Antigen in Immune Complexes Is Boosted by Soluble Bacterial Immunoglobulin Binding Proteins. Journal of Experimental Medicine, 1999, 189, 1217-1228.	4.2	11
151	FcÎ³RIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP). Leukemia, 2004, 18, 2038-2040.	3.3	11
152	Expression of low-affinity Fc gamma receptor by a human metastatic melanoma line. Immunology Letters, 2000, 75, 1-8.	1.1	10
153	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in Immunology, 2011, 2, 66.	2.2	9
154	B cells and complement at the forefront of chemotherapy. Nature Reviews Clinical Oncology, 2020, 17, 393-394.	12.5	9
155	EFISâ€EJI supported events: Courses, Schools, Symposia and Meetings with a European flavour. European Journal of Immunology, 2011, 41, 2467-2469.	1.6	8
156	50th Anniversary of the French Society for Immunology (SFI). European Journal of Immunology, 2016, 46, 1545-1547.	1.6	8
157	Animal Models of Intraocular Lymphomas. Ophthalmic Research, 2008, 40, 208-211.	1.0	7
158	700O Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N). Annals of Oncology, 2020, 31, S553.	0.6	7
159	Inhibition of Human Immunodeficiency Virus Transmission to CD4+T Cells after Gene Transfer of Constitutively Expressed Interferon Î² to Dendritic Cells. Human Gene Therapy, 2000, 11, 1695-1703.	1.4	5
160	EFIS: Driving women's representation in immunology in Europe. European Journal of Immunology, 2014, 44, 615-616.	1.6	5
161	Mouse models of primary central nervous system lymphomas: tools for basing funding and therapeutic strategies. Journal of Neuro-Oncology, 2015, 121, 9-18.	1.4	5
162	Complement Detection in Human Tumors by Immunohistochemistry and Immunofluorescence. Methods in Molecular Biology, 2021, 2227, 191-203.	0.4	5

#	Article	IF	Citations
163	NIVOREN GETUG-AFU 26 translational study: CD8 infiltration and PD-L1 expression are associated with outcome in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) treated with nivolumab (N). Annals of Oncology, 2019, 30, v360-v361.	0.6	4
164	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. Methods in Enzymology, 2020, 632, 15-25.	0.4	3
165	The immune microenvironments of lung and intraocular tumors. Bulletin Du Cancer, 2011, 98, E58-E61.	0.6	2
166	The 2011 Nobel Prize in Physiology or Medicine: Honor, sadness and lessons. European Journal of Immunology, 2011, 41, 3393-3393.	1.6	2
167	Tumor Immunology, toward a Success Story?. Frontiers in Immunology, 2015, 6, 65.	2.2	2
168	The Human Tumor Microenvironment. , 2018, , 5-21.		2
169	Editorial: Tertiary Lymphoid Structures: From Basic Biology to Translational Impact in Cancer. Frontiers in Immunology, 2022, 13, 870862.	2.2	2
170	EFISâ€ŒJI Ruggero Ceppelini Advanced Immunology School Course: Tumour immunology 2017: From tissue microenvironment to immunotherapy. Naples 16â€“18 October 2017. European Journal of Immunology, 2018, 48, 559-561.	1.6	1
171	Primary Central Nervous System Lymphomas (PCNSL) Are Distinct from Systemic DLBCL for Expression Pattern of Germinal Center and Activation B-Cell Markers. A GOELAMS Study.. Blood, 2004, 104, 2264-2264.	0.6	1
172	Immuno-molecular characterization of colorectal cancer tumors and its clinical implications. Translational Cancer Research, 2016, 5, S368-S370.	0.4	1
173	Super C3-convertases, formed by gain-of-function factor B or C3 mutant proteins are associated with atypical haemolytic uraemic syndrome with a poor outcome. Molecular Immunology, 2008, 45, 4098-4099.	1.0	0
174	The European Academy of Tumor Immunology: Bridging fields, continents and generations. OncoImmunology, 2012, 1, 127-128.	2.1	0
175	Intratumoral classical complement pathway promotes tumor growth in renal cancer. Molecular Immunology, 2018, 102, 205.	1.0	0
176	NEMIO: A randomized phase II trial evaluating efficacy and safety of dose dense MVAC (ddMVAC) + durvalumab +/- tremelimumab as neoadjuvant treatment in patients with bladder muscle-invasive urothelial carcinoma. Annals of Oncology, 2019, 30, v400-v401.	0.6	0
177	Abstract IA20: Cancer subtypes and their immune microenvironments. , 2016, , .		0
178	Abstract A085: Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary clear cell renal cell cancer. , 2016, , .		0
179	Abstract LB-273: Identity card of tumor-infiltrating regulatory T cells in the context of tertiary lymphoid structures in lung cancer patients. , 2016, , .		0
180	Abstract IA10: Tumor microenvironments: Prognostic and theranostic impacts. , 2016, , .		0

#	Article	IF	Citations
181	Les structures lymphoÃ¯des tertiaires gÃ©nÃ¨rent et propagent des plasmocytes produisant desÂanticorps antitumoraux dans le cancer du rein. Medecine/Sciences, 2022, 38, 536-538.	0.0	0